Derpanicate is cholesterol inhibitor. It was developed for the treatment of hyperlipidaemia. Preregistration was discontinued in Italy and Switzerland.

Democonazole is the antimycotic agent.

Demelverine is an antispasmodic agent and bronchodilator.

Deloxolone was devoid of aldosterone-like properties. Deloxolone could be of therapeutic value in peptic ulcer diseases without inducing fluid retention, hypertension and hypokaliemia. Carbenoxolone and deloxolone were orally administered to healthy volunteers in a cross-over double-blind trial. Both the concentration in gastric juice and the output of PGE2, determined by an RIA method in basal conditions and after pentagastrin bolus, increased in drug-treated compared to vehicle-treated subjects thus supporting the hypothesis that cytoprotection might be due to gastric PGE, levels. Moreover, deloxolone induced less marked effects than carbenoxolone on body weight, hematocrit, plasma potassium and proteins, confirming that deloxolone is less similar to aldosterone than the reference drug.

Cyclazodone is a stimulant drug developed by American Cyanamid Company. Administration of the drug led to an increase in spontaneous activity. The compound is claimed to be useful as a psychotonic drug in depressive states, anxiety, as an anti-fatigue agent, and as an anorexigenic drug. The compound is included in the World Anti-Doping Agency prohibited list.

Conessine is a plant steroid alkaloid that acts as a potent and specific antagonist of histamine H3 receptors. Conessine displayed high affinity at both rat and human H3 receptors (pKi = 7.61 and 8.27) and generally high selectivity against other sites, including histamine receptors H1, H2, and H4. Conessine was found to efficiently penetrate the CNS and reach very high brain concentrations. Although the very slow CNS clearance and strong binding to adrenergic receptors discouraged focus on conessine itself for further development, its potency and novel steroid-based skeleton motivated further chemical investigation. Modification based on introducing diversity at the 3-nitrogen position generated a new series of H3 antagonists with higher in vitro potency, improved target selectivity, and more favorable drug-like properties. Conessine also has high affinity for the adrenergic receptors. Conessine has being shown to possess anti-malarial activity. In India conessine finds therapeutic use for treatment of dysentery and helminthic disorders.

Clostebol is a synthetic anabolic-androgenic steroid, a derivative of the natural hormone testosterone. Clostebol is a Schedule III controlled substance used medically in topical ophthalmologic and dermatologic treatments. Due to potential use as a performance-enhancing drug, clostebol is banned by the World Anti-Doping Agency.

Hydrobentizide is a diuretic.

Pexacerfont is a highly potent and selective CRF1 receptor antagonist that displays no agonist properties. It is specific for CRF1 receptors and has more than 1,000- fold less affinity for CRF2 receptors, and more than 100- fold less affinity for the CRF-binding protein. In extensive preclinical studies, pexacerfont has been shown to inhibit specific binding of CRF to rat, dog, monkey, and human CRF1 receptors. The functional anxiolytic effects of CRF1 receptor occupancy were demonstrated in two rodent models of anxiety, situational anxiety and elevated plus maze paradigms. Pexacerfont did not demonstrate efficacy compared to placebo for the treatment of generalized anxiety disorder in human. The bogus taste tests suggested some protective effect of pexacerfont against eating after a laboratory stressor. Pexacerfont had been in phase II clinical trials for the treatment of irritable bowel syndrome and depression depression.

Aventis developed safironil as a competitive inhibitor of collagen protein synthesis for the treatment of liver disorders. This compound participated in phase I clinical trial for the treatment of cirrhosis in Germany. In addition, it was studied for hepatic fibrosis treatment. However, information about the further development of this compound is not available.